Search

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement today regarding financial results for the six months ended June 30, 2023.

… Tuesday, August 15, 2023 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement today regarding financial results for the six months ended June 30, 2023:    MSK’s financial performance for the six months ended June 30, 2023, demonstrated continued improvement in operating results

Memorial Sloan Kettering Cancer Center (MSK) is partnering with PathPresenter, a leader in digital pathology workflow software, to integrate DeepLIIF, MSK’s new artificial intelligence (AI) algorithm, into PathPresenter’s image management platform for oncology research.

… Monday, April 14, 2025 Memorial Sloan Kettering Cancer Center (MSK) is partnering with PathPresenter, a leader in digital pathology workflow software, to integrate DeepLIIF, MSK’s new artificial intelligence (AI) algorithm, into PathPresenter’s image management platform for oncology research. DeepLIIF

… Thursday, October 6, 2022 Perry Ortiz doesn’t remember having a seizure in 2016. Or being rushed to an operating room, where doctors confirmed Perry — a security supervisor at Memorial Sloan Kettering Cancer Center (MSK) — had stage 2 testicular cancer . His only recollection of that day six years ago

The US Food and Drug Administration has updated its recommendations for the use of Gardasil 9, the vaccine that protects against human papillomavirus (HPV), to include people age 27 to 45. Previously, Gardasil 9 was only approved for use in those between age nine and 26. 

… Thursday, October 18, 2018 The US Food and Drug Administration has updated its recommendations for the use of Gardasil 9, the vaccine that protects against human papillomavirus (HPV), to include people age 27 to 45. Previously, Gardasil 9 was only approved for use in those between age nine and 26.  This

Read about a new discovery that could lead to more powerful cell-based therapies for cancer.

… Tuesday, July 22, 2025 A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically engineered immune cells sometimes fail to finish the job when given as a cancer treatment. The new discovery sheds light on the tendency of these modified cells

Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer.

… Wednesday, October 17, 2012 Summary Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer. Construction on the Mortimer B. Zuckerman Research Center – named in recognition of the $100

The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.

… Tuesday, January 5, 2021 The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma.  The drug , also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering

美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物也称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。

… Tuesday, January 5, 2021 美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物 也被称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。 Naxitamab 的临床试验由儿科肿瘤医生 Brian Kushner 和 MSK 斯隆儿科项目的神经母细胞瘤团队主导开展。 如今美国和全球的患者将更容易获得这种治疗。 神经母细胞瘤 是一种罕见的神经组织癌症，通常源于腹部。 其主要影响幼儿群体。 尽管过去这种疾病在几乎所有的高危病例中都是致命的，但在过去的二十年中，其前景得到了相当大的改善

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder cancer (NMIBC).

… Monday, April 29, 2024 MSK Clinical Trials for Patients with BCG-Naïve, BCG-Exposed, and BCG-Unresponsive Bladder Cancer Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

… Friday, October 25, 2013 Summary Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients. Despite tremendous advances in medical research in recent decades, the number of new treatments that